Evidence map›Paper›PMID 35530130›Full record

ReviewActa pharmaceutica Sinica. B2022

The generation of PD-L1 and PD-L2 in cancer cells: From nuclear chromatin reorganization to extracellular presentation.

Zhiwei Fan, Changyue Wu, Miaomiao Chen, Yongying Jiang, Yuanyuan Wu, Renfang Mao, Yihui Fan

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Two cases of rare immune-related cystitis glandularis induced by tislelizumab.The Journal of international medical research · 2026
    Article
  7. Article
  8. Review
  9. Article
  10. Intracellular PD-L1: Functions, Regulation, and Therapeutic Implications.International journal of biological sciences · 2026
    Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Zhiwei FanDepartment of Pathogenic Biology, School of Medicine, Nantong University, Nantong 226001, China.
Changyue WuLaboratory of Medical Science, School of Medicine, Nantong University, Nantong 226001, China.
Miaomiao ChenLaboratory of Medical Science, School of Medicine, Nantong University, Nantong 226001, China.
Yongying JiangDepartment of Pathophysiology, School of Medicine, Nantong University, Nantong 226001, China.
Yuanyuan WuLaboratory of Medical Science, School of Medicine, Nantong University, Nantong 226001, China.
Renfang MaoDepartment of Pathophysiology, School of Medicine, Nantong University, Nantong 226001, China.
Yihui FanDepartment of Pathogenic Biology, School of Medicine, Nantong University, Nantong 226001, China.
Nantong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The immune checkpoint blockade (ICB) targeting on PD-1/PD-L1 has shown remarkable promise in treating cancers. However, the low response rate and frequently observed severe side effects limit its broad benefits. It is partially due to less understanding of the biological regulation of PD-L1. Here, we systematically and comprehensively summarized the regulation of PD-L1 from nuclear chromatin reorganization to extracellular presentation. In PD-L1 and PD-L2 highly expressed cancer cells, a new TAD (topologically associating domain) (chr9: 5,400,000-5,600,000) around

Indexed as

3′-UTR, 3′-untranslated regionADAM17, a disintegrin and metalloprotease 17APCs, antigen-presenting cellsAREs, adenylate and uridylate (AU)-rich elementsATF3, activating transcription factor 3CD273/274, cluster of differentiation 273/274CDK4, cyclin-dependent kinase 4CMTM6, CKLF like MARVEL transmembrane domain containing 6CSN5, COP9 signalosome subunit 5CTLs, cytotoxic T lymphocytesdMMR, deficient DNA mismatch repairEMT, epithelial to mesenchymal transitionEpCAM, epithelial cell adhesion moleculeExosomeFACS, fluorescence-activated cell sortingGSDMC, Gasdermin CGSK3β, glycogen synthase kinase 3 betaHi-C, high throughput chromosome conformation captureHSF1, heat shock transcription factor 1ICB, immune checkpoint blockadeIFN, interferonIL-6, interleukin 6Immune checkpoint blockadeirAEs, immune related adverse eventsIRF1, interferon regulatory factor 1JAK, Janus kinase 1NFκB, nuclear factor kappa BNSCLC, non-small cell lung cancerOTUB1, OTU deubiquitinase, ubiquitin aldehyde binding 1PARP1, poly(ADP-ribose) polymerase 1PD-1, programmed cell death-1PD-L1PD-L1, programmed death-ligand 1PD-L2PD-L2, programmed death ligand 2Post-transcriptional regulationPost-translational regulationSP1, specificity protein 1SPOP, speckle-type POZ proteinSTAG2, stromal antigen 2STAT3, signal transducer and activator of transcription 3T2D, type 2 diabetesTADs, topologically associating domainsTFEB, transcription factor EBTFs, transcription factorsTNFα, tumor necrosis factor-alphaTopologically associating domainTranscriptionTTP, tristetraprolinUCHL1, ubiquitin carboxy-terminal hydrolase L1USP22, ubiquitin specific peptidase 22

Identifiers

PMID35530130
PMCPMC9069407
OpenAlexW3199831921

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.